STOCK TITAN

BioSig Technologies Inc SEC Filings

BSGM Nasdaq

Welcome to our dedicated page for BioSig Technologies SEC filings (Ticker: BSGM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The BSGM SEC filings archive on Stock Titan presents the regulatory record of the company formerly known as BioSig Technologies, Inc., which has since rebranded as Streamex Corp. and now trades under the symbol STEX. These documents trace the company’s transition from a medical device technology issuer to a business focused on real-world asset and gold tokenization.

Key filings include multiple Current Reports on Form 8-K detailing material events such as the merger with Streamex Exchange Corporation, the amendment to the certificate of incorporation changing the corporate name to Streamex Corp., and the Nasdaq ticker symbol change from BSGM to STEX. Other 8-K filings describe the secured convertible debenture purchase agreement with an institutional investor, the issuance of an initial tranche of convertible debentures, and related security and registration rights agreements.

The archive also contains a definitive proxy statement on Form DEF 14A for the company’s annual meeting, which outlines proposals including director elections, executive compensation advisory votes, auditor ratification, and amendments to the long-term incentive plan. Additional filings report amendments to the certificate of incorporation to increase authorized shares and to classify the board into staggered terms, as well as a tokenized yield partnership agreement related to precious-metal lease and bond programs.

On Stock Titan’s filings page, investors can review these historical BSGM documents alongside AI-powered summaries that explain the main terms, structures, and implications of each report. The feed updates as new Streamex Corp. (STEX) filings appear in the SEC’s EDGAR system, allowing users to follow the company’s ongoing regulatory disclosures, including future 10-K annual reports, 10-Q quarterly reports, and any Form 4 insider transaction filings associated with the successor entity.

Rhea-AI Summary

Streamex Corp. has fully settled its secured convertible debentures with YA II PN, LTD., ending this financing arrangement and related security interests. On February 6, 2026, the holder converted $15,000,000 of principal at $4.00 per share, issuing 3,750,000 common shares under an existing shelf registration.

After the conversion window expired, Streamex prepaid the remaining amounts for a total of $38,902,740, including $35,000,000 of principal, a $3,500,000 prepayment premium, and $402,740 of accrued interest. The company also cancelled its unused Standby Equity Purchase Agreement with Yorkville, describing these steps as removing debt and dilution overhang and leaving a clean balance sheet.

Governance-wise, co-founder and Chairman Morgan Lekstrom has been appointed Executive Chairman and joins the executive leadership team, with compensation details to be determined. Streamex also filed a prospectus supplement to register for resale 2,443,750 previously issued common shares held by Terra Capital Natural Resources Fund Pty Ltd.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Streamex Corp. has registered 2,443,750 shares of common stock for resale by Terra Capital Natural Resources Fund Pty Ltd. These shares were issued under a Share Purchase Agreement in exchange for 12,671,297 Empress Royalty Corp. shares, representing a 9.9% Empress stake valued at $12,218,751.

This is a secondary offering, so Streamex will not receive proceeds from any resale; Terra Capital will receive the sale proceeds and pay any selling commissions, while Streamex covers registration expenses. The filing also highlights Streamex’s dual focus on tokenized gold-linked finance and its legacy PURE EP medical device platform, alongside substantial historical losses, going-concern warnings, and extensive regulatory, liquidity, and leverage risks tied to its gold tokenization and prior debt financings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus
-
Rhea-AI Summary

Streamex Corp. appointed Anthony Marciano, a Clinical Professor of Finance at NYU Stern, as an independent director and member of the Audit Committee. His term runs until the next annual stockholder meeting or until a successor is elected and qualified.

Marciano brings more than 40 years of experience in finance and academics, including senior roles at Goldman Sachs, Morgan Stanley, and Drexel Burnham Lambert, and teaching positions at NYU Stern, MIT Sloan, and the University of Chicago. Under Streamex’s current non-employee director policy, he will receive a $40,000 annual cash retainer plus $25,000 per Board committee, and is eligible for annual equity awards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Streamex Corp. reported an insider share purchase linked to major shareholder Frank Giustra. On February 4, 2026, an entity called Frank Giustra 2018 SSAS, over which he has voting and dispositive control, bought 100,000 shares of common stock at $3.17 per share. Following this transaction, the entity indirectly holds 1,278,205 Streamex Corp. shares for which Giustra is the reporting person and a more than 10% owner.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Streamex Corp. director and 10% owner Morgan Lekstrom reported buying 23,500 shares of common stock at $3.06 per share on February 3, 2026. The shares are held indirectly through All Mine Consulting Ltd, bringing his reported indirect beneficial ownership to 102,500 Streamex common shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Streamex Corp reported an insider share purchase by an affiliated entity. On 01/29/2026, All Mine Consulting Ltd, an entity for which director and 10% owner Morgan Lekstrom holds voting and dispositive control, purchased 2,500 shares of Streamex common stock at $3.70 per share. Following this transaction, the entity indirectly holds 79,000 shares of common stock for Lekstrom’s benefit.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Frank Giustra, a more than 10% owner of Streamex Corp., reported an indirect purchase of common stock. On January 23, 2026, an entity named Frank Giustra 2018 SSAS bought 1,000,000 shares of Streamex Corp. common stock at $3 per share.

Following this transaction, the filing shows 1,178,205 shares of common stock indirectly beneficially owned through that entity, over which Giustra holds voting and dispositive control.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Streamex Corp. entered into an Underwriting Agreement with Needham & Company for a public offering of 11,666,667 shares of common stock at $3.00 per share. The offering, made under an effective Form S-3 shelf registration, closed after the shares were sold to the underwriters.

On January 27, 2026, the underwriters fully exercised their over-allotment option to purchase an additional 1,750,000 shares at the public offering price, bringing aggregate gross proceeds to the company to $40.25 million before underwriting discounts and expenses. The company plans to use net proceeds to repay prior indebtedness, and for working capital and general corporate purposes.

The agreement includes customary representations, indemnification provisions, and a 60-day lock-up under which the company, as well as its officers and directors, agreed not to offer or transfer common stock, subject to specified exceptions. Streamex also obtained a legal opinion on the validity of the shares and issued multiple press releases announcing the launch, pricing, closing, and over-allotment closing of the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Streamex Corp. terminated its Standby Equity Purchase Agreement with YA II PN, Ltd. (“Yorkville”), effective five trading days after a January 22, 2026 notice, and confirmed it has not sold any securities under that facility. The company also moved to fully address its secured convertible debentures held by Yorkville.

On the same date, Streamex delivered an irrevocable optional prepayment notice for its secured convertible debentures dated November 4 and December 17, 2025, with an original aggregate principal amount of $50,000,000. Yorkville has ten trading days from the notice date to elect conversion, after which any remaining balance must be prepaid at principal plus a 10% prepayment premium and accrued interest, with related security interests released once paid in full.

The company disclosed that, if conversions are not completed before the prepayment date, it may liquidate allocated vaulted gold bullion credited to a pledged account to fund the prepayment. Streamex furnished a press release about the SEPA termination and debenture repayment as Exhibit 99.1, noting this information is being furnished rather than filed for Exchange Act liability purposes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Summary

Streamex Corp. director and 10% owner Morgan Lekstrom reported an indirect purchase of common stock. On 01/27/2026, an entity he controls, All Mine Consulting Ltd, bought 5,500 shares of Streamex Corp. common stock at $3.12 per share, coded as an open-market or private purchase ("P").

After this transaction, All Mine Consulting Ltd held a total of 76,500 shares of Streamex Corp. common stock, over which Lekstrom has voting and dispositive control, and the holdings are reported as indirect ownership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of BioSig Technologies (BSGM)?

The current stock price of BioSig Technologies (BSGM) is $6.1 as of September 11, 2025.

What is the market cap of BioSig Technologies (BSGM)?

The market cap of BioSig Technologies (BSGM) is approximately 157.0M.
BioSig Technologies Inc

Nasdaq:BSGM

BSGM Rankings

BSGM Stock Data

156.96M
25.09M
28.73%
28.66%
4.96%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
WESTPORT

BSGM RSS Feed